UroMems
UroMems is a French medtech company developing the UroActive® System, the first smart automated artificial urinary sphincter using its proprietary MEMS platform to treat stress urinary incontinence in men and women. The device is pre-commercial and currently in U.S. and European pivotal clinical trials.
- Company typePrivate
- Founded2011
- HeadquartersGrenoble, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What UroMems does
UroMems is a privately held medtech company founded in 2011 in Grenoble, France, with a U.S. headquarters in Minneapolis. The company is developing a single product, the UroActive® System — the first smart automated artificial urinary sphincter (AUS) intended to treat stress urinary incontinence (SUI) in both men and women. UroActive is powered by the company's proprietary MyoElectroMechanical System (MEMS) platform, which embeds micro-sensors, electronics, and algorithms inside the implant to continuously measure patient activity and automatically adjust urethral pressure without manual intervention. The device also includes a remote control interface allowing patients to manage voiding and pressure settings.
The UroActive System is currently investigational and not yet authorized for sale in any market. It has not received CE marking under EU MDR 2017/745 or FDA marketing authorization; however, in July 2025 the company received FDA Investigational Device Exemption (IDE) approval and French ANSM clearance to begin the SOPHIA2 pivotal clinical trial at 21 investigational centers across the U.S. and France. The company also holds FDA Safer Technologies Program (STeP) designation for the device. Once cleared, the intended go-to-market is direct hospital sales to urology and urogynecology departments, where trained surgeons would implant the device.
UroMems is pre-revenue and venture-funded. Cumulative disclosed funding exceeds $147 million across multiple equity rounds (notably a $47M Series C in June 2024 led by Crédit Mutuel Innovation, and a $60M strategic investment in May 2026 led by Ajax Health Fund I) plus a non-dilutive EIC Accelerator grant in late 2023. The company employs 60+ engineers and clinical specialists, holds 180+ patents/applications worldwide, and has built clinical partnerships with leading academic centers including La Pitié-Salpêtrière, Vanderbilt, Duke, and Mayo Clinic. Key board additions in 2024–2026 (Dan Rose as Chairman, Rinda Sama, and Ajax Health representatives) reflect investor positioning toward commercialization.
UroMems firmographics
Firmographics- Name
- UroMems
- Legal name
- UroMems SAS
- Website
- https://uromems.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- UroMems is a French medtech company developing the UroActive® System, the first smart automated artificial urinary sphincter using its proprietary MEMS platform to treat stress urinary incontinence in men and women. The device is pre-commercial and currently in U.S. and European pivotal clinical trials.
- Ownership category
- akta.pro rank
UroMems industry classification
Industry- Product category
- Urological Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Reconstructive Urology & Urethral Stricture Care (HLAKAOAH)
- akta.pro secondary industries
- Endourology & Minimally Invasive Urologic Surgery (HLAKAOAF), General Urology (HLAKAOAA)
Keywords
Where UroMems is headquartered
LocationHeadquarters
- HQ city
- Grenoble
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
UroMems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel
Revenue model
- UroActive Smart Implant Commercialization: Pre-revenue medical device company developing UroActive, a smart automated artificial urinary sphincter for treating stress urinary incontinence. Revenue will be generated through device sales to hospitals and clinics once regulatory approvals are obtained in the U.S. and European markets. The product is not yet available for sale as it is under clinical evaluation.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
UroMems product offering
Product offeringCore offering
UroMems develops and plans to commercialize the UroActive System, the first smart automated artificial urinary sphincter (AUS) for treating stress urinary incontinence (SUI) in men and women. Powered by the company's proprietary MyoElectroMechanical System (MEMS) platform, the implant is placed around the urethral duct and automatically adjusts urethral pressure in real time based on patient activity measured by embedded micro-sensors. The device is currently under clinical investigation and has not yet received marketing authorization in the U.S. or EU.
Product overview
UroMems is a single-product company developing the UroActive® System, the first smart automated artificial urinary sphincter (AUS) for treating stress urinary incontinence (SUI) in both men and women. The device is powered by a proprietary MyoElectroMechanical System (MEMS) technology platform that combines embedded smart, AI-based, digital and robotic systems. The UroActive System automatically adjusts urethral pressure based on real-time patient activity data collected by micro-sensors, creating personalized treatment algorithms for each patient. The product is currently under clinical investigation and has not received marketing authorization from FDA or EU regulators.
Differentiator
Problem solved
Functional benefit
Brands
- UroActive®: The first smart automated artificial urinary sphincter (AUS) powered by MyoElectroMechanical System (MEMS) technology to treat stress urinary incontinence (SUI) in men and women.
Products and services
- UroActive System The UroActive System is the first smart automated artificial urinary sphincter (AUS) powered by UroMems' proprietary MyoElectroMechanical System (MEMS) technology, designed to treat stress urinary incontinence in men and women. The implant is placed around the urethral duct and automatically adjusts urethral pressure in real time based on patient activity measured by embedded micro-sensors, eliminating the need for manual adjustments and reducing tissue damage from constant pressure. The system is intended for adult patients with SUI and is operated by an intuitive patient remote control.
Quantifiable outcome
- All 6 male feasibility study patients showed devices operating as expected with no need for revision nor explant for 7-15 months
- +3 more outcomes
Companies that use UroMems
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles1 record
UroMems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
UroMems partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Vanderbilt UniversitycoreCo-principal U.S. investigator site for SOPHIA2 pivotal trial with Dr. Melissa Kaufman serving as principal investigator.
- Duke UniversitycoreCo-principal U.S. investigator site for SOPHIA2 pivotal trial with Dr. Drew Peterson serving as principal investigator.
- La Pitié-Salpêtrière University HospitalcoreKey clinical trial site for first-in-human and first-in-female UroActive implants. Professor Emmanuel Chartier-Kastler serves as principal investigator and clinical advisor.
- Nantes University HospitalcoreClinical trial site for first-in-man study of UroActive System.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
UroMems competitors and assessment
Company assessmentDirect peers
- Axonics (acquired by Boston Scientific): Axonics developed sacral neuromodulation implants for urge/overflow incontinence and fecal incontinence before being acquired by Boston Scientific in 2024 for ~$3.7B. Closest analog to UroMems as a venture-backed, single-indication implantable incontinence company that achieved breakthrough scale and was acquired by a strategic - UroMems' near-term trajectory (pivotal trial, ASP positioning, BSX as potential acquirer) closely mirrors Axonics' pre-acquisition arc.
- Laborie Medical Technologies: Laborie is a private-equity-owned urology-focused medtech company (backed by Patricia Industries/Investor AB) with deep presence in urodynamics, pelvic floor, and male incontinence diagnostics and devices. It is a direct competitor profile as a urology-specialty company selling to the same urologist and urogynecologist call points that UroMems is targeting.
- Caldera Medical: Caldera Medical is a venture-backed women's health medtech focused on surgical solutions for stress urinary incontinence and pelvic organ prolapse (mesh and biologic implants). It serves the same female-SUI patient pool with a surgical-urology approach, making it one of the most relevant direct peers for UroMems' targeted female SUI indication.
Broad incumbents
- Boston Scientific: Boston Scientific owns the AMS 800 artificial urinary sphincter - the entrenched gold-standard AUS for male SUI - as well as Axonics' SNM systems for urge incontinence. As the dominant incumbent and the party most likely to either acquire UroMems or launch a defensive next-gen AUS, it is the central strategic reference point for UroMems' market opportunity.
- Coloplast: Coloplast is a global incumbent in continence care, with a large portfolio of urinary catheters, external collection devices, and surgical sling products, plus a substantial sales force calling on urologists. While it does not currently offer an active AUS, it is the reference incumbent UroMems must disintermediate in the hospital channel.
- Cook Medical: Cook Medical is a privately held diversified medtech with a dedicated urology specialty business (including ureteral stents, stone management, and continence products). The breadth of its urology portfolio and its physician relationships make it a comparable broad-urology incumbent that could enter the smart-AUS category or be a potential strategic acquirer.
- Ethicon (Johnson & Johnson): Ethicon, J&J's surgical franchise, markets mid-urethral sling meshes and other pelvic floor repair products for female SUI. As a large medtech incumbent with the channel and clinical footprint to scale a competing SUI device, it is a key broader competitor and potential acquirer of UroMems.
- Convatec: Convatec is a global medtech with a Continence Care business unit selling catheters, ostomy, and continence products. While focused on disposable rather than active implantable solutions, it is a relevant strategic comparable in the broader urinary-incontinence treatment ecosystem and a potential adjacent acquirer.
- B. Braun Melsungen: B. Braun is a diversified European medtech with a significant urology franchise (Uromed catheters, Ureofix, and other continence/intermittent catheter products). It shares UroMems' European medtech heritage and is a relevant comparable for urology product portfolio strategies and European commercialization paths.
Emerging players
- Atlantic Therapeutics: Atlantic Therapeutics is an emerging player selling INNOVO, a non-invasive electrical muscle stimulation device for SUI. Although it targets a different point on the treatment pathway (conservative therapy rather than surgical AUS), it competes for the same SUI patient population and represents an alternative-technology emerging competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
UroMems social profiles
Digital presenceUroMems compliance and trust
Trust signalCompliance4 records
UroMems financial estimates
Financial estimateRevenue estimate
Valuation estimate
UroMems leadership team
Management profileNumber of profiles
Profiles15 records
UroMems funding detail
Funding detailFunding overview
Funding rounds8 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
UroMems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about UroMems
What does UroMems do?
UroMems develops and plans to commercialize the UroActive System, the first smart automated artificial urinary sphincter (AUS) for treating stress urinary incontinence (SUI) in men and women. Powered by the company's proprietary MyoElectroMechanical System (MEMS) platform, the implant is placed around the urethral duct and automatically adjusts urethral pressure in real time based on patient activity measured by embedded micro-sensors. The device is currently under clinical investigation and has not yet received marketing authorization in the U.S. or EU.
Is UroMems a public or private company?
UroMems is a private company. It is classified as venture growth investor backed and is currently operating.
When was UroMems founded?
UroMems was founded in 2011. It employs 11 to 50 people.
Where is UroMems based?
UroMems is headquartered in Grenoble, France, in the Europe region.
How does UroMems make money?
One revenue line is on record: uroActive Smart Implant Commercialization.
Who are UroMems's main competitors?
Direct peers on record are Axonics (acquired by Boston Scientific), Laborie Medical Technologies and Caldera Medical. Broad incumbents are Boston Scientific, Coloplast, Cook Medical, Ethicon (Johnson & Johnson), Convatec and B. Braun Melsungen. Atlantic Therapeutics is listed as an emerging player.
Does UroMems have an API?
No public API is recorded for UroMems.
What industry is UroMems in?
UroMems's product category is Urological Medical Devices. Its primary akta.pro industry code is HLAKAOAH, Reconstructive Urology & Urethral Stricture Care, with a secondary code of HLAKAOAF, Endourology & Minimally Invasive Urologic Surgery. Its NAICS code is 339113 and its SIC code is 3842.